Phase 1 trial of QRL-201 for promoting neuronal growth commences.
QurAlis has announced the dosing of the first patient in a Phase 1 clinical trial evaluating QRL-201, an experimental antisense oligonucleotide molecule in treating amyotrophic lateral sclerosis (ALS). The study is the first into a potential therapy that works to increase production of stathmin-2 (STMN2), a protein needed for neuronal growth and repair. The trial is expected to enroll up to 64 adults with ALS, ages 18 to 80, and no SOD1 or FUS gene mutations at sites in Canada, Europe, and the U.S.